The priority of points in this release does seem to put cessation last :
"– the impact of nadolol on biomarkers of airway inflammation, β-arrestin pathway activation and abnormal mucus production;
– the safety and efficacy of nadolol as an aid to smoking cessation in patients with increased cough and sputum (phlegm) production who have repeatedly failed to quit; and
– the correlation of biomarkers of airway healing with cigarette smoking reduction or cessation, in order to optimise the nadolol regimen and patient selection for planned phase III clinical trials."
and further, page-45
Add IVX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
-0.001(9.09%) |
Mkt cap ! $32.12M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.5¢ | $56.69K | 11.33M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 32 | 21500000 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 12125188 | 4 |
View Market Depth
| Last trade - 13.28pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
0.5¢ |
Change
-0.001 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 0.5¢ | 0.5¢ | 0.5¢ | 100000 | ||
| Last updated 10.04am 24/05/2024 ? | |||||
| IVX (ASX) Chart |